Year-end report January - December 2009

Fourth quarter 2009 • Net sales decreased by 9 percent to 99.5 MSEK (109.0). At comparable exchange rates sales decreased by 5 percent. • The operating result amounted to 3.6 MSEK (15.0). Before reversal of restructuring reserve, the operating result amounted to 0,4 MSEK (15.0). • Additional purchase payment from Qiagen for the Biosystems business area divested in 2008 was obtained to the amount of 23.4 MSEK. • The result after tax amounted to 28.1 MSEK (265.1). • Earnings per share amounted to 0.32 SEK (3.00). • Net cash at December 31, 2009 amounted to 327.2 MSEK. • Biotage repurchased 1,419,330 own shares at a total value of 9.1 MSEK, i.e. an average share price of 6.40 SEK. • The cash flow from operating activities amounted to 18.4 MSEK (50.7). Full year 2009 • Net sales increased by 2 percent to 394.1 MSEK (385.3). At comparable exchange rates sales decreased by 9 percent. • The sales development for consumables has been good during 2009 with increases for the product lines SNA and SPE. The year has been weak for capital goods with declining sales of instruments. • The operating result amounted to -10.1 MSEK (27.2). Before restructuring costs the operating result amounted to 7.9 MSEK (27.2). • Additional purchase payment from Qiagen for the Biosystems business area divested in 2008 was obtained to the amount of 23.4 MSEK. • The result after tax amounted to 13.5 MSEK (299.1). • Earnings per share amounted to 0.15 SEK (3.38). • Dividends to shareholders were paid to the amount of 17.7 MSEK. • As a part of Biotage’s buy-back program 1,578,109 own shares were repurchased at a total value of 10.2 MSEK, i.e. an average share price of 6.45 SEK. • The cash flow from operating activities amounted to 36.2 MSEK (88.7). • Proposed dividends 0.20 SEK (0.20) For further information, please contact: Torben Jörgensen, president and CEO, phone: +46 707 49 05 84 Mats-Olof Wallin, CFO, phone: +46 705 93 52 73